Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Mupirocin

FDA-approved product (ointment, topical), marketed as Bactroban, Centany, Mupirocin.

Registered studies
50+
Lab records
16
Pathogens at ≥40%
4 of 4

Chemical structure

Chemical structure of Mupirocin
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Impetigo
  • Infection
  • Nasal congestion

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Other antibiotics for topical use; Other nasal preparations
FDA pharmacologic class
RNA Synthetase Inhibitor Antibacterial FDA label ↗
Anti-infective classification
Classified as an existing antimicrobial.WHO ATC D06AX09; FDA class RNA Synthetase Inhibitor Antibacterial

Repurposing investigation

Mupirocin is already an antimicrobial, so it is not counted among the repurposing candidates. Its AI-predicted activity is shown below for reference.

AI-predicted activity

AI prediction · nothing measured
  • MRSA75.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • E. coli82.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • K. pneumoniae71.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • M. tuberculosis42.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

  • MRSA: measured active in 6 of 10 lab records
  • E. coli: measured active in 1 of 2 lab records
  • K. pneumoniae: measured active in 2 of 4 lab records
Open Mupirocin in ChEMBL Registered studies below
Show the 16 laboratory records, with sources

Loading records…

“Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Mupirocin with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Prophylaxis Prior to Cataract Surgery Conjunctival Flora and Optimal Ocular Sterilization Technique Prior to Cataract Surgery

    NCT00406913 · start 2005-10

    Registered record
    Registry ID
    NCT00406913
    Conditions
    Endophthalmitis; Cataract Surgery; Prophylaxis
    Interventions
    mupirocin ointment; SOC sterilization
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2005-10
    Completion
    2006-11
    Enrolment
    37

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEndophthalmitis; Cataract Surgery; Prophylaxis
    Interventionmupirocin ointment; SOC sterilization
    PhaseNot applicable
    Registry statusCompleted

  • The Impact of Treating Staphylococcus Aureus Infection and Colonization on the Clinical Severity of Atopic Dermatitis

    NCT00179959 · start 2005-09

    Registered record
    Registry ID
    NCT00179959
    Conditions
    Atopic Dermatitis
    Interventions
    Sodium hypochlorite (bleach) baths; Mupirocin ointment; Water; Petrolatum Ointment
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2005-09
    Completion
    2011-03
    Enrolment
    31

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAtopic Dermatitis
    InterventionSodium hypochlorite (bleach) baths; Mupirocin ointment; Water; Petrolatum Ointment
    PhasePhase 4
    Registry statusCompleted

  • Preventing Staphylococcal (Staph) Infection

    NCT00108160 · start 2005-04

    Registered record
    Registry ID
    NCT00108160
    Conditions
    Staphylococcal Infections
    Interventions
    Mupirocin Ointment [Treatment]; Polyethylene Glycol Ointment [Placebo]
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2005-04
    Completion
    2012-08
    Enrolment
    146

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionStaphylococcal Infections
    InterventionMupirocin Ointment [Treatment]; Polyethylene Glycol Ointment [Placebo]
    PhasePhase 4
    Registry statusCompleted

  • An Attempt to Reduce Community-Acquired Methicillin-Resistant Staphylococcus Aureus (MRSA) Infection in Soldiers

    NCT00289588 · start 2005-01

    Registered record
    Registry ID
    NCT00289588
    Conditions
    Community-Acquired MRSA Infections; Abscesses; Cellulitis; Folliculitis
    Interventions
    Mupirocin (drug)
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2005-01
    Completion
    2005-12
    Enrolment
    3,000

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCommunity-Acquired MRSA Infections; Abscesses; Cellulitis; Folliculitis
    InterventionMupirocin (drug)
    PhaseNot applicable
    Registry statusCompleted

  • Prophylaxis With Intranasal Mupirocin for Prevention of S. Aureus Infections

    NCT00156377 · start 2002-11

    Registered record
    Registry ID
    NCT00156377
    Conditions
    Cross Infection; Staphylococcal Infections
    Interventions
    Mupirocin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2002-11
    Completion
    Not recorded
    Enrolment
    1,200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCross Infection; Staphylococcal Infections
    InterventionMupirocin
    PhasePhase 4
    Registry statusCompleted